A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study.

Br J Haematol 2018 02 21;180(3):445-448. Epub 2016 Sep 21.

Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Davis, CA, USA.

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360527PMC
February 2018
7 Reads

Publication Analysis

Top Keywords

patients myelodysplastic
4
724770 patients
4
nsc 724770
4
trap aflibercept
4
myelodysplastic syndrome
4
syndrome california
4
consortium study
4
cancer consortium
4
california cancer
4
factor trap
4
aflibercept nsc
4
study vascular
4
endothelial growth
4
growth factor
4
phase study
4
vascular endothelial
4
california
1
endothelial
1
consortium
1
study
1

References

(Supplied by CrossRef)
Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
Fiedler et al.
Blood 1997

Similar Publications